{"id":420,"date":"2025-11-21T01:11:20","date_gmt":"2025-11-20T18:11:20","guid":{"rendered":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/"},"modified":"2025-11-21T01:11:20","modified_gmt":"2025-11-20T18:11:20","slug":"ready-or-not-biopharma-alignment-for-cnpvs-rapid-review","status":"publish","type":"post","link":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/","title":{"rendered":"Ready or Not: Biopharma Alignment for CNPV\u2019s Rapid Review"},"content":{"rendered":"
<\/p>\n

Editor’s Note:<\/em>
Check out additional coverage and industry expert perspectives in “

And check out “How the FDA Commissioner\u2019s National Priority Vouchers Reshape Manufacturing, Pricing & Global Strategy<\/astro-island>,” as well as “Winners & Losers: What the First FDA Commissioner\u2019s National Priority Vouchers Tell Us About Early Movers vs. Late Movers”<\/astro-island><\/em>\u00a0from our colleagues over at Pharmaceutical Executive.<\/em><\/p>\n

The FDA Commissioner\u2019s National Priority Voucher (CNPV) pilot program represents a tectonic shift in the expectations placed upon biopharmaceutical sponsors seeking market entry (1). The program, which utilizes a “collaborative tumor board style review process” and a “multidisciplinary team-based evaluation,” offers the benefit of reducing application review times from the traditional 8-12 months to “just 1-2 months” following submission (1,2). As Commissioner Marty Makary, MD, MPH, stated, the process is intended to use a \u201ccommon-sense approach… so that we can reduce inefficiencies” and harness a “tumor board style” discussion to deliver “timely decisions for drug developers” (2). However, this unprecedented acceleration mandates that companies must entirely dismantle the traditional sequential launch model and replace it with a demanding framework of pre-submission completion and parallel cross-functional execution, according to industry experts we spoke with.<\/p>\n

Does the CNPV program require a shift to a parallel execution model?<\/strong><\/h2>\n

The most critical realization for CNPV applicants is that the compressed timeline eliminates the luxury of sequential product launch activities. In a PharmTech Group<\/em> interview, Henrik Johanning, senior vice president, Quality & Strategy, Epista Life Science, summarizes this radical necessity, stating \u201cWhen review windows shrink from 10-12 months to as little as 1-2 months, the entire model for launch readiness changes.\u201d He stresses that \u201cthe traditional sequential approach, in which regulatory, chemistry, manufacturing, and controls (CMC), labeling, and market access teams work in turn, no longer works.”<\/p>\n

To succeed under this accelerated timeline, Johanning says companies need to \u201cshift to a parallel execution model, in which quality, regulatory, and commercial readiness progress in lockstep.\u201d This shift, he notes, \u201cdemands mature governance and disciplined cross-functional coordination long before submission.\u201d Metin \u00c7elik, PhD, president, Pharmaceutical Technologies International, Inc (PTI), reiterates this point in a PharmTech Group<\/em> interview, stating unequivocally that when the regulatory clock compresses, companies \u201cmust fundamentally shift key launch-readiness activities to the pre-submission stage.\u201d<\/p>\n

This necessity entails a high degree of integration across internal departments, \u00c7elik adds, which should operate through \u201cintegrated readiness \u2018war rooms\u2019 with weekly cross-functional reviews across CMC, regulatory, safety, medical, commercial, and supply chain.\u201d The ultimate determinant of success in this accelerated environment, according to Johanning, is not the voucher itself, but \u201chow companies structure their internal control and decision-making models to make compressed reviews sustainable.\u201d<\/p>\n

Why is pre-submission perfection in CMC and quality systems so critical?<\/strong><\/h2>\n

The cornerstone of the CNPV’s speed is the mandatory pre-submission requirement: participants must submit the CMC portion of their application (or efficacy supplement (ES)) and their proposed labeling “at least 60 days before submitting their complete application\/ES” (1,2). This front-loading of technical information means that manufacturing and quality robustness must be near perfection at the time of filing.<\/p>\n

\u00c7elik clarifies that manufacturing and supply chain readiness, encompassing \u201ctech transfer, process performance qualification, control strategy, domestic\/dual sourcing, quality system robustness, \u2026must be essentially complete at submission.\u201d The penalty for non-compliance, he adds, is severe given the time constraint, \u201cwith a potential 30-60-day review, there is no time to fix compliance gaps once the file is submitted.\u201d Johanning adds that compressed timelines \u201camplify every weakness in a company\u2019s quality risk management (QRM) framework.\u201d Therefore, he continues, the most prepared organizations “use QRM not only as a compliance tool, but as a decision-making compass.”<\/p>\n

Companies must mitigate these risks proactively. \u00c7elik recommends that they \u201cinvest early in CMC strength and supply chain resilience\u201d and utilize systems for \u201cstructured risk assessments, documentation frameworks, and predictive readiness analytics aligned with FDA expectations.\u201d Johanning advises that sponsors \u201crun a risk-based readiness sprint before applying.\u201d This sprint, he says, involves critical steps like locking \u201cCMC and control strategies, verifying tech-transfer and supply-chain qualification (ideally US-based), aligning labeling and process validation plans, and ideally rehearsing day-0 to day-30 responses,\u201d because \u201cthe clock starts the moment you file.\u201d<\/p>\n

In an interview with PharmTech Group<\/em>, Aloka Srinivasan, principal and managing partner at Raaha LLC\u2014who has helped a CNPV winner with their application and paperwork and is now getting them ready for the project\u2014reinforces that while the formal review time shrinks, it \u201cdoes not imply that product development, marketing preparation, or post-approval planning must also be compressed proportionally.\u201d Instead, the expectation is that by the time the application is submitted, \u201cboth the sponsor and the Agency should already have resolved key risks, making approval largely a formality.\u201d For generic products, Srinivasan notes, the CMC information could be provided \u201cmany months in advance,\u201d leaving bioequivalence as potentially \u201cthe only major remaining issue to address after the formal submission.\u201d<\/p>\n

The complexity also extends to external logistics, such as facility inspections. Rory Budihandojo, an independent good manufacturing practices consultant, notes in a PharmTech Group<\/em> interview that it is “not clear how the FDA (alters) other activities to get the drugs to the market faster (e.g., getting the pre-approval inspection, or PAI, coordinated within that 1-2 months frame).” This uncertainty further pressures sponsors to ensure proactive inspection preparation, which \u00c7elik calls “mission critical.”<\/p>\n

How must commercial and pricing strategies integrate with the CNPV\u2019s affordability mandate?<\/strong><\/h2>\n

Beyond technical readiness, commercial and market access strategies must also be accelerated. \u00c7elik insists that \u201cmarket access strategy, pricing scenarios, health economics and outcomes research (HEOR) models, and payer engagement must begin during late-phase clinical development\u2014not after filing.\u201d Furthermore, he says, “labeling strategy and competitive positioning require early alignment because the opportunity for iterative dialogue with FDA becomes limited.” Srinivasan confirms that sponsors \u201cwill need to advance market access, pricing, and post-approval readiness activities in parallel.\u201d<\/p>\n

Crucially, commercial strategy must integrate one of the CNPV\u2019s explicit criteria: Increasing affordability (1). FDA specifies that this \u201ccould include a company that lowers the U.S. price of a drug or reduces other downstream medical utilization to lower overall healthcare costs\u201d (1,3) Makary also notes that vouchers are granted when the company has “agreed to increase affordability” (4).<\/p>\n

Sarah Emond and Daniel Ollendorf characterized this focus on cost as a \u201cmarked and notable departure for the FDA, an agency that has been clear in the past that drug costs are not its purview or responsibility\u201d in Health Affairs Scholar<\/em> (3). They noted that the Makary\u2019s statement included the concept of agreeing to price the drug under \u201cMost Favored Nation\u201d drug pricing, pointing out that this concept is \u201cproblematic because the United States is frequently where new drugs are launched first, so in most cases, there would not be any other prices to reference\u201d (3). Instead of relying on foreign pricing mechanics, Emond and Ollendorf proposed an innovative solution: “drugs approved through the pathway should be required to be priced to value,” an approach they said ensures that \u201ca price charged society by the drug manufacturer is tied to how much better it makes patients feel\u201d (3).<\/p>\n

Emond and Ollendorf explained that the use of cost-effectiveness analysis, a cornerstone of value assessment, \u201ccan summarize the costs a new drug would introduce to the system, the savings it might provide by keeping patients out of the hospital or emergency room, and how it might improve both survival and quality of life during treatment\u201d (3). This analysis \u201ccan suggest a fair and affordable price for the benefits a drug provides, which aligns with the spirit of the Commissioner’s statement\u201d (3). Companies seeking the CNPV must prepare to demonstrate alignment with these affordability metrics during the late stages of clinical development, long before the application is submitted, adds \u00c7elik.<\/p>\n

How should companies leverage enhanced communication and adjust regulatory mindsets?<\/strong><\/h2>\n

A key benefit provided to CNPV participants is “enhanced communication throughout the review process” and the use of a rolling review (1). This elevated level of interaction is designed to expedite the process by proactively addressing issues.<\/p>\n

Srinivasan characterizes this interaction as a \u201cparadigm change, especially for generics, that needs better understanding.\u201d She states that generic companies that \u201care usually not used to communicating with the Agency to the extent that do new drug sponsors, will now need to change their mindset and be ready to do so.\u201d<\/p>\n

Sponsors must treat these frequent pre-submission discussions strategically, Srinivasan says, advising sponsors to \u201cshift in mindset to take advantage of this support,\u201d treating these interactions as they would handle “information requests” or \u201cdiscipline-specific\u201d inquiries received after the submission of the dossier. For non-complex generics, this communication represents a \u201crare luxury as a sponsor of such products has very few ways of communicating with the Agency prior to submission,\u201d she adds. The CNPV, says Srinivasan, guarantees \u201cnumerous opportunities to discuss the product and process with the Agency prior to submission of the dossier and the expectation is that by the time they submit the dossier, hopefully most of the issues have been resolved.\u201d<\/p>\n

Where does the strategic benefit of onshoring drug development lie?<\/strong><\/h2>\n

A primary national priority driving the CNPV program is \u201conshoring drug development and manufacturing to advance the health interests of Americans and strengthen U.S. supply chain resiliency\u201d (1,2). This priority, according to FDA, addresses the concern that “the vast majority of the active pharmaceutical ingredients and drug components in Americans\u2019 everyday medicines are supplied from China” (2).<\/p>\n

Johanning details the strategic goals of the onshoring criteria, explaining that the FDA is using the program \u201cto steer advanced manufacturing, especially sterile injectables and biologics, back to the US.\u201d The overarching objective, he says, is \u201cto rebuild domestic pharmaceutical capacity after decades of off-shoring to Asia and Eastern Europe.\u201d Specific aims, he continues, include reducing \u201cstrategic dependency on single-region, non-U.S. suppliers for APIs and sterile products,\u201d safeguarding \u201ccritical manufacturing know-how,\u201d and encouraging \u201cmodernization, using US-based continuous-manufacturing or single-use technologies.\u201d Furthermore, according to Johanning, US-based facilities \u201care easier for FDA to inspect, monitor, and support during scale-up or remediation.\u201d This effort, adds Budihandojo, also provides incentives for firms to “invest and build facilities in the US.”<\/p>\n

Srinivasan affirms that the on-shoring benefit is \u201cespecially high for generics and biosimilars,\u201d granting them the valuable \u201csignificant opportunities to communicate with FDA prior to their submissions.\u201d Johanning clarifies that the focus is less about nationality and \u201cmore about where and how you produce.\u201d Thus, foreign firms with “mature GMP systems” can qualify as \u201cvoucher-ready\u201d if they “can demonstrate US manufacturing capacity, tech-transfer readiness, and quality oversight aligned with FDA expectations.” The CNPV offers a faster path to market for companies that execute this parallel model effectively, provided they have performed the requisite \u201ccareful planning,\u201d concludes Srinivasan.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. FDA. Commissioner’s National Priority Voucher (CNPV) Pilot Program<\/astro-island>. Accessed Nov 18, 2025.<\/li>\n
  2. FDA. FDA to Issue New Commissioner\u2019s National Priority Vouchers to Companies Supporting U.S. National Interests<\/astro-island>. Press Release. June 17, 2025.<\/li>\n
  3. Emond, S; Ollendorf, D. How to Make One Line in the FDA Commissioner’s New Drug Review Program Into a Force for Affordable Access for Patients<\/astro-island>. Health Aff Sch<\/em>. 2025;3(10):qxaf182.<\/li>\n
  4. FDA. FDA Awards Second Batch of National Priority Vouchers<\/astro-island>. Press Release. Nov 6, 2025.<\/li>\n<\/ol><\/div>\n","protected":false},"excerpt":{"rendered":"

    Editor’s Note:Check out additional coverage and industry expert perspectives in “The Regulatory Crucible: Risk, Resource Drain, and the Hidden Trade-Offs of the CNPV Pilot Program.” And check out “How the FDA Commissioner\u2019s National Priority Vouchers Reshape Manufacturing, Pricing & Global Strategy,” as well as “Winners & Losers: What the First FDA Commissioner\u2019s National Priority Vouchers […]<\/p>\n","protected":false},"author":1,"featured_media":421,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-420","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"yoast_head":"\nReady or Not: Biopharma Alignment for CNPV\u2019s Rapid Review - Nova Anggreni, S.Farm, APT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/\" \/>\n<meta property=\"og:locale\" content=\"id_ID\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ready or Not: Biopharma Alignment for CNPV\u2019s Rapid Review - Nova Anggreni, S.Farm, APT\" \/>\n<meta property=\"og:description\" content=\"Editor’s Note:Check out additional coverage and industry expert perspectives in “The Regulatory Crucible: Risk, Resource Drain, and the Hidden Trade-Offs of the CNPV Pilot Program.” And check out “How the FDA Commissioner\u2019s National Priority Vouchers Reshape Manufacturing, Pricing & Global Strategy,” as well as “Winners & Losers: What the First FDA Commissioner\u2019s National Priority Vouchers […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/\" \/>\n<meta property=\"og:site_name\" content=\"Nova Anggreni, S.Farm, APT\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-20T18:11:20+00:00\" \/>\n<meta name=\"author\" content=\"pythonsonline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ditulis oleh\" \/>\n\t<meta name=\"twitter:data1\" content=\"pythonsonline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimasi waktu membaca\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 menit\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/\"},\"author\":{\"name\":\"pythonsonline\",\"@id\":\"https:\/\/pythonsonline.com\/#\/schema\/person\/c1dd578cabc4e398492d9e25f7aff156\"},\"headline\":\"Ready or Not: Biopharma Alignment for CNPV\u2019s Rapid Review\",\"datePublished\":\"2025-11-20T18:11:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/\"},\"wordCount\":1861,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/pythonsonline.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/11\/ce2b9d110468723f1ba012b8a13c91abcedbc2e8-5244x2860-scaled.jpg\",\"articleSection\":[\"Blog\"],\"inLanguage\":\"id\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/\",\"url\":\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/\",\"name\":\"Ready or Not: Biopharma Alignment for CNPV\u2019s Rapid Review - Nova Anggreni, S.Farm, APT\",\"isPartOf\":{\"@id\":\"https:\/\/pythonsonline.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/11\/ce2b9d110468723f1ba012b8a13c91abcedbc2e8-5244x2860-scaled.jpg\",\"datePublished\":\"2025-11-20T18:11:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#breadcrumb\"},\"inLanguage\":\"id\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"id\",\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#primaryimage\",\"url\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/11\/ce2b9d110468723f1ba012b8a13c91abcedbc2e8-5244x2860-scaled.jpg\",\"contentUrl\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/11\/ce2b9d110468723f1ba012b8a13c91abcedbc2e8-5244x2860-scaled.jpg\",\"width\":2560,\"height\":1396},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Beranda\",\"item\":\"https:\/\/pythonsonline.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ready or Not: Biopharma Alignment for CNPV\u2019s Rapid Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pythonsonline.com\/#website\",\"url\":\"https:\/\/pythonsonline.com\/\",\"name\":\"Nova Anggreni, S.Farm, APT\",\"description\":\"Keahlian Farmasi Bertemu Kekuatan Python\",\"publisher\":{\"@id\":\"https:\/\/pythonsonline.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pythonsonline.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"id\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/pythonsonline.com\/#organization\",\"name\":\"Nova Anggreni, S.Farm, APT\",\"url\":\"https:\/\/pythonsonline.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"id\",\"@id\":\"https:\/\/pythonsonline.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/04\/novapylogo.png\",\"contentUrl\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/04\/novapylogo.png\",\"width\":1080,\"height\":416,\"caption\":\"Nova Anggreni, S.Farm, APT\"},\"image\":{\"@id\":\"https:\/\/pythonsonline.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/pythonsonline.com\/#\/schema\/person\/c1dd578cabc4e398492d9e25f7aff156\",\"name\":\"pythonsonline\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"id\",\"@id\":\"https:\/\/pythonsonline.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ce18169fbfa6b96654e8a84f663d2fe6cd783a46c25e8318605272fd245c2e8c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ce18169fbfa6b96654e8a84f663d2fe6cd783a46c25e8318605272fd245c2e8c?s=96&d=mm&r=g\",\"caption\":\"pythonsonline\"},\"sameAs\":[\"https:\/\/pythonsonline.com\"],\"url\":\"https:\/\/pythonsonline.com\/index.php\/author\/pythonsonline\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ready or Not: Biopharma Alignment for CNPV\u2019s Rapid Review - Nova Anggreni, S.Farm, APT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/","og_locale":"id_ID","og_type":"article","og_title":"Ready or Not: Biopharma Alignment for CNPV\u2019s Rapid Review - Nova Anggreni, S.Farm, APT","og_description":"Editor’s Note:Check out additional coverage and industry expert perspectives in “The Regulatory Crucible: Risk, Resource Drain, and the Hidden Trade-Offs of the CNPV Pilot Program.” And check out “How the FDA Commissioner\u2019s National Priority Vouchers Reshape Manufacturing, Pricing & Global Strategy,” as well as “Winners & Losers: What the First FDA Commissioner\u2019s National Priority Vouchers […]","og_url":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/","og_site_name":"Nova Anggreni, S.Farm, APT","article_published_time":"2025-11-20T18:11:20+00:00","author":"pythonsonline","twitter_card":"summary_large_image","twitter_misc":{"Ditulis oleh":"pythonsonline","Estimasi waktu membaca":"9 menit"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#article","isPartOf":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/"},"author":{"name":"pythonsonline","@id":"https:\/\/pythonsonline.com\/#\/schema\/person\/c1dd578cabc4e398492d9e25f7aff156"},"headline":"Ready or Not: Biopharma Alignment for CNPV\u2019s Rapid Review","datePublished":"2025-11-20T18:11:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/"},"wordCount":1861,"commentCount":0,"publisher":{"@id":"https:\/\/pythonsonline.com\/#organization"},"image":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#primaryimage"},"thumbnailUrl":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/11\/ce2b9d110468723f1ba012b8a13c91abcedbc2e8-5244x2860-scaled.jpg","articleSection":["Blog"],"inLanguage":"id","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/","url":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/","name":"Ready or Not: Biopharma Alignment for CNPV\u2019s Rapid Review - Nova Anggreni, S.Farm, APT","isPartOf":{"@id":"https:\/\/pythonsonline.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#primaryimage"},"image":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#primaryimage"},"thumbnailUrl":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/11\/ce2b9d110468723f1ba012b8a13c91abcedbc2e8-5244x2860-scaled.jpg","datePublished":"2025-11-20T18:11:20+00:00","breadcrumb":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#breadcrumb"},"inLanguage":"id","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/"]}]},{"@type":"ImageObject","inLanguage":"id","@id":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#primaryimage","url":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/11\/ce2b9d110468723f1ba012b8a13c91abcedbc2e8-5244x2860-scaled.jpg","contentUrl":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/11\/ce2b9d110468723f1ba012b8a13c91abcedbc2e8-5244x2860-scaled.jpg","width":2560,"height":1396},{"@type":"BreadcrumbList","@id":"https:\/\/pythonsonline.com\/index.php\/2025\/11\/21\/ready-or-not-biopharma-alignment-for-cnpvs-rapid-review\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Beranda","item":"https:\/\/pythonsonline.com\/"},{"@type":"ListItem","position":2,"name":"Ready or Not: Biopharma Alignment for CNPV\u2019s Rapid Review"}]},{"@type":"WebSite","@id":"https:\/\/pythonsonline.com\/#website","url":"https:\/\/pythonsonline.com\/","name":"Nova Anggreni, S.Farm, APT","description":"Keahlian Farmasi Bertemu Kekuatan Python","publisher":{"@id":"https:\/\/pythonsonline.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pythonsonline.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"id"},{"@type":"Organization","@id":"https:\/\/pythonsonline.com\/#organization","name":"Nova Anggreni, S.Farm, APT","url":"https:\/\/pythonsonline.com\/","logo":{"@type":"ImageObject","inLanguage":"id","@id":"https:\/\/pythonsonline.com\/#\/schema\/logo\/image\/","url":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/04\/novapylogo.png","contentUrl":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/04\/novapylogo.png","width":1080,"height":416,"caption":"Nova Anggreni, S.Farm, APT"},"image":{"@id":"https:\/\/pythonsonline.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pythonsonline.com\/#\/schema\/person\/c1dd578cabc4e398492d9e25f7aff156","name":"pythonsonline","image":{"@type":"ImageObject","inLanguage":"id","@id":"https:\/\/pythonsonline.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ce18169fbfa6b96654e8a84f663d2fe6cd783a46c25e8318605272fd245c2e8c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ce18169fbfa6b96654e8a84f663d2fe6cd783a46c25e8318605272fd245c2e8c?s=96&d=mm&r=g","caption":"pythonsonline"},"sameAs":["https:\/\/pythonsonline.com"],"url":"https:\/\/pythonsonline.com\/index.php\/author\/pythonsonline\/"}]}},"_links":{"self":[{"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/posts\/420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/comments?post=420"}],"version-history":[{"count":0,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/posts\/420\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/media\/421"}],"wp:attachment":[{"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/media?parent=420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/categories?post=420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/tags?post=420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}